Abstract
Background: Nuclear factor-κB (NF-κB) plays a pivotal role in restenosis after percutaneous coronary intervention (PCI) and the aim of the present clinical trials was to evaluate the effectiveness of a NF-κB decoy for preventing restenosis. Methods and Results: The initial case was a patient suffering from effort angina who had stenoses in the proximal and middle portions of the right coronary artery. The patient received 2 stents; the NF-κB decoy was delivered to the distal site, but not the proximal site. Six months after the PCI, the NF-κB decoy had suppressed restenosis in comparison with the no-decoy transfection site. The second case was a patient who underwent single-stent insertion and decoy transfection at the same site, and minimal intimal thickening was observed at 6 month after PCI. No systemic adverse effects were observed in either case. Conclusion: These results indicate the clinical usefulness and safety of NF-κB decoy transfection after PCI, but further evaluations are necessary to confirm its clinical effectiveness.
| Original language | English |
|---|---|
| Pages (from-to) | 270-271 |
| Number of pages | 2 |
| Journal | Circulation Journal |
| Volume | 68 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Mar 1 2004 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Cardiology and Cardiovascular Medicine
Cite this
Initial Clinical Cases of the Use of a NF-κB Decoy at the Site of Coronary Stenting for the Prevention of Restenosis. / Suzuki, Jun Ichi; Ito, Hiroshi; Gotoh, Ryo; Morishita, Ryuichi; Egashira, Kensuke; Isobe, Mitsuaki.
In: Circulation Journal, Vol. 68, No. 3, 01.03.2004, p. 270-271.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Initial Clinical Cases of the Use of a NF-κB Decoy at the Site of Coronary Stenting for the Prevention of Restenosis
AU - Suzuki, Jun Ichi
AU - Ito, Hiroshi
AU - Gotoh, Ryo
AU - Morishita, Ryuichi
AU - Egashira, Kensuke
AU - Isobe, Mitsuaki
PY - 2004/3/1
Y1 - 2004/3/1
N2 - Background: Nuclear factor-κB (NF-κB) plays a pivotal role in restenosis after percutaneous coronary intervention (PCI) and the aim of the present clinical trials was to evaluate the effectiveness of a NF-κB decoy for preventing restenosis. Methods and Results: The initial case was a patient suffering from effort angina who had stenoses in the proximal and middle portions of the right coronary artery. The patient received 2 stents; the NF-κB decoy was delivered to the distal site, but not the proximal site. Six months after the PCI, the NF-κB decoy had suppressed restenosis in comparison with the no-decoy transfection site. The second case was a patient who underwent single-stent insertion and decoy transfection at the same site, and minimal intimal thickening was observed at 6 month after PCI. No systemic adverse effects were observed in either case. Conclusion: These results indicate the clinical usefulness and safety of NF-κB decoy transfection after PCI, but further evaluations are necessary to confirm its clinical effectiveness.
AB - Background: Nuclear factor-κB (NF-κB) plays a pivotal role in restenosis after percutaneous coronary intervention (PCI) and the aim of the present clinical trials was to evaluate the effectiveness of a NF-κB decoy for preventing restenosis. Methods and Results: The initial case was a patient suffering from effort angina who had stenoses in the proximal and middle portions of the right coronary artery. The patient received 2 stents; the NF-κB decoy was delivered to the distal site, but not the proximal site. Six months after the PCI, the NF-κB decoy had suppressed restenosis in comparison with the no-decoy transfection site. The second case was a patient who underwent single-stent insertion and decoy transfection at the same site, and minimal intimal thickening was observed at 6 month after PCI. No systemic adverse effects were observed in either case. Conclusion: These results indicate the clinical usefulness and safety of NF-κB decoy transfection after PCI, but further evaluations are necessary to confirm its clinical effectiveness.
UR - http://www.scopus.com/inward/record.url?scp=1642545592&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1642545592&partnerID=8YFLogxK
U2 - 10.1253/circj.68.270
DO - 10.1253/circj.68.270
M3 - Article
C2 - 14993786
AN - SCOPUS:1642545592
VL - 68
SP - 270
EP - 271
JO - Circulation Journal
JF - Circulation Journal
SN - 1346-9843
IS - 3
ER -